Skip to Content

Omnicell, Inc. (NASDAQ:OMCL) is the tenth largest holding of Avory & Company LLC.

Omnicell, Inc. (NASDAQ:OMCL) is the tenth largest holding of Avory & Company LLC.

The most recent filing that Avory & Company LLC made with the Securities and Exchange Commission reveals that during the third quarter, the company reduced its holdings of Omnicell, Inc. (NASDAQ: OMCL) by 18.1%. As a result of the business selling 11,949 shares of company stock during the period covered by the report, the company now has a total ownership stake of 54,248 shares in the company. Avery & Company LLC is the tenth largest holder of Omnicell because it accounts for approximately 4.0 percent of the company’s investment portfolio. This places Omnicell in the tenth position among the company’s holdings. Avery & Company LLC held approximately 0.12% of Omnicell at the end of the most recent reporting period, with a value of $4,721,000. This was equivalent to the value of the holding at the end of the previous reporting period.

Several other hedge funds have also changed their stakes in the company in the most recent period. Vanguard Group Inc. raised the proportion of its holdings in Omnicell by 0.3 percentage points over the first three months of 2018. Vanguard Group Inc. now holds 4,752,906 shares of the company’s stock, which has a value of $615,453,000 due to the purchase of an additional 12,413 shares during the most recent fiscal quarter. This brings the total number of shares owned by the company to 4,752,906. In the second quarter, Macquarie Group Ltd. brought the total amount of Omnicell stock that it owned to a level that was 12.5% higher than before. Macquarie Group Ltd. now has 1,218,279 shares following the purchase of an additional 135,360 shares during the most recent quarter. The value of these shares brings the company’s overall holdings to a total of $138,579,000. Clearbridge Investments LLC expanded its holdings in Omnicell by 1.2% during the year’s second quarter by purchasing additional company shares. Following the acquisition of an additional 13,809 shares during the most recent quarter, Clearbridge Investments LLC now holds 1,150,473 shares of the company’s stock in its portfolio. The stock holdings of Clearbridge Investments LLC have a value of $130,864,000 as of right now. During the second quarter, Lazard Asset Management LLC witnessed a rise of 1,045.9% in the amount of Omnicell stock it could call its own. Lazard Asset Management LLC now holds 884,541 shares following the purchase of an additional 807,348 last quarter. The value of these shares, as of the present moment, is $100,616,000. And finally, during the first three months of this year, Dimensional Fund Advisors LP increased the amount of Omnicell stock held by 0.6%. After purchasing an additional 4,839 shares during the most recent quarter, Dimensional Fund Advisors LP now holds 848,688 of the company’s shares, which have an aggregate value of $109,901,000. This brings the total number of shares that the firm owns to 848,688.

Several research analysts’ reports on OMCL stock have recently been published on their websites. Benchmark’s recommendation for Omnicell has been changed from “buy” to “hold,” according to a research note published on November 3. JPMorgan Chase & Co. lowered the price objective for Omnicell from $140.00 to $57.00 and assigned the stock a “neutral” rating in a research report published on Friday, November 18. Craig Hallum decreased their price objective on Omnicell from $185.00 to $75.00 in a report that was published on Thursday, November 3. The rating that StockNews.com has assigned to Omnicell shares has been changed from “sell” to “hold” due to a research study published on Friday and made available to the general public. In a research report released on Friday, November 4, Wells Fargo & Company rated the company as “overweight” and decreased their price target on Omnicell shares from $158.00 to $71.00. The report also gave the company an “overweight” rating. In comparison, four research analysts have given the company a “hold” rating, while five have given the company a “buy” rating. The information provided by Bloomberg indicates that the consensus opinion regarding Omnicell is to “Moderately Buy” the company’s stock and that the average price target for the stock is $82.11.

NASDAQ: OMCL was first available for trading on Friday with an opening price of $55.48. A price-to-earnings ratio of 54.39, a price-to-earnings-growth ratio of 4.86, and a beta value of 0.89 are all associated with the stock. The company’s total value, as represented by its market capitalization, is $2.46 billion. Over the last 52 weeks, the highest and lowest prices for Omnicell, Inc. have been equal, coming in at $168.18. The ratio of debt to equity is 0.50, the ratio of quick ratio to current ratio is 1.86, and the ratio of current ratio to quick ratio is 2.25. The price of a share of stock’s 50-day moving average is currently $50.42, while its 200-day moving average is $81.76, respectively.

On November 2, the most recent earnings report for Omnicell, which is publicly traded and can be found under the symbol NASDAQ: OMCL, was made available to the public. The actual earnings per share generated by the company for the quarter came in at $0.70, which is $0.04 higher than the consensus estimate among industry professionals, which was $0.66. However, the revenue for the quarter came in at $348.06 million, which was significantly lower than the $362.72 million that analysts had anticipated. When we looked at their financials, Omnicell had a return on equity of 9.74% and a net margin of 3.67%. Sell-side analysts forecast that Omnicell, Inc. will generate $1.62 per share earnings throughout the current fiscal year.

On December 1, Randall A. Lipps, the company’s CEO, sold 2,500 of the company’s shares of stock. This is just one of the latest developments relating to this topic. On December 1, the shares were sold at a volume that resulted in a total sale of $126,950.00 of company stock. The average price per share that was received for them was $50.78. The price per share, sold at an average of $50.78, brought in a total of $126,950.00 for the transaction’s volume. After the deal’s completion, the Chief Executive Officer will be the direct owner of 88,348 shares. The total value of these shares is approximately $4,486,311.44, so the CEO’s stake in the company will be worth about that much. You can find a document that explains the transaction in greater detail on the Securities and Exchange Commission (SEC) website. In other recent business-related news, on December 1, Randall A. Lipps, Chief Executive Officer of the company, sold 2,500 shares of the company’s stock. This news comes as part of a recent development. It was determined that the price of $50.78 per share was the average price paid for the shares, which resulted in a total of $126,950.00 being acquired from the sale of the shares. Following the successful sale conclusion, the Chief Executive Officer is now the direct owner of 88,348 shares, which have a value of $4,486,311.44. If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed, and it will take you there immediately.

On top of that, Executive Vice President Scott Peter Seidelmann sold 4,436 shares of the company’s stock on December 16. The sale of the stock resulted in total revenue of $211,996.44, with the average price at which each share could be purchased being $47.79. The Executive Vice President is the sole owner of 30,733 company shares with a combined value of $1,468,730.07. The disclosure related to the sale might be found in this website section. During the most recent quarter, the company’s insiders sold 9,674 shares of company stock for a total value of $476,839 in stock transactions. This constitutes 2.76 percent of the total number of shares that are currently outstanding.

The medication management solutions and adherence tools provided by Omnicell, Inc. and its subsidiaries are offered for use in healthcare systems and pharmacies in the United States and other countries around the world. Automated dispensing systems for operating rooms that are part of the XT Series; automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital that are part of the XT Series; the Omnicell Interface Software, which provides interface and integration between its medication-use products or supply products and a healthcare system; and automated dispensing systems for operating rooms that are part of the XT Series.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *